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IMPORTANCE
It has been reported the low level of active P-TEFb critically contributes to the maintenance of 2 HIV-1 latency or low-replication in HIV-1 reservoir cells under cART. Bromodomain inhibitors 3 are used to activate HIV-1 replication in vitro but their effect on activation of the HIV-1 4 resevoirs with cART in vivo is not clear. We found that BETi (I-BET151) treatment reactivated 5 HIV-1 gene expression in humanized mice during suppressive cART. Interestingly, I-BET151 6 preferentially reactivated HIV-1 gene expression in monocytic cells, but not in CD4 T cells. 7 Furthermore, I-BET151 significantly increased HIV-1 transcription in monocytic cells, but not in 8 latently infected CD4 T cells, via CDK2-dependent mechanisms. Our findings suggest that BETi 9 can preferentially activate monocytic HIV-1 reservoir cells, and a combination of latency 10 reversal agents targeting different cell types and pathways is needed to achieve reactivation of 11 different HIV-1 reservoir cells during cART. 1 The global implementation of cART has transformed HIV infection from a fatal disease into a 2 manageable chronic illness, and successfully blunted HIV pandemic (1) (2) (3) . HIV-1 replication can 3 be suppressed and maintained at a level below the detection limits by current cART regimens. 4 However, cART is still unable to cure HIV-1 infection. Drug resistance, serious non-AIDS events 5 as well as financial and societal issues associated with life-long cART highlight the urgent need 6 in finding a cure for the disease (4-7). Therefore, recent efforts have focused on interventions 7 that can yield a drug-free remission of HIV-1 replication or even eradication of replication-8 competent HIV-1 proviruses in patients. 9 The obstacle to eradicate HIV-1 is the persistence of latent or low replicating HIV-1 reservoirs. 10 Following discontinuation of cART, HIV-1 reservoirs are able to produce infectious viral particles, 11 result in viral relapse (8) (9) (10) (11) . The molecular mechanisms associated with the maintenance and 12 reactivation of HIV latency have been extensively investigated, including transcriptional 13 interference, deleterious mutations in the viral genome, low levels of transcriptional activators, 14 inadequate Tat activity, epigenetics, transcriptional repressors engagement, nucleosome 15 positioning, mRNA splicing or nuclear export blocks as well as cellular microRNA (12, 13) . It is 16 most likely that multiple mechanisms are involved in HIV-1 reservoirs persistence. And the 17 relative importance of these mechanisms in different cell types is remain to be determined. 18 The best characterized HIV-1 cellular reservoir is the long-lived resting CD4 + T lymphocytes 19 harboring quiescent proviral DNA that is replication-competent upon reactivation. However, 20 reservoirs in myeloid cells could be a problem for curative strategies targeting to resting CD4 + T 21 cells only. Macrophages are susceptible to HIV-1 infection in human and animal models(14-17), 1 and HIV-1 could be recovered from the circulating monocytes pool of patients treated with 2 cART (18, 19) . In addition, HIV-1 is able to infect and replicate in brain astrocytes and microglia 3 cells in a restricted manner that could persist despite cART (20, 21) . And recent reports 4 demonstrated that humanized mice with myeloid cells only allow HIV-1 persistent infection in 5 macrophages during cART in vivo(17), and integrated HIV-1 DNA can be detected in the bone 6 marrow and spleen macrophages in humanized mice with suppressive cART (22) . These findings 7 highlight that, other than resting CD4 + T cells, monocytes or macrophages are of great clinical 8 importance in terms of HIV-1 cure. 9 It is known that bromodomain-containing protein 4 (BRD4) competes P-TEFb and disrupts the 10 interaction between Tat and P-TEFb, and forfeits the ability of Tat to trans-activate HIV-1 11 transcription (23) (24) (25) . Given the important role of P-TEFb in regulating HIV gene expression, 12 different BETi have been explored and tested to activate HIV-1 gene expression in latent 13 models of primary CD4 + T cells, lymphocytic T cell lines and monocytic cell lines (26, 27) . 14 However, little is known about the therapeutic potential of BETi in activating viral replication in 15 HIV-1 reservoirs during cART in vivo. 16 In this study, we tested how bromodomain inhibitor (I-BET151) affected viral replication in 17 HIV-1 reservoir cells in vivo during suppressive antiretroviral therapy. Our results demonstrate 18 that I-BET151 treatment leads to reactivation of HIV-1 gene expression preferentially in 19 monocytic cells during cART, which highlights the therapeutic potential of bromodomain 20 inhibitors to activate the unique monocytic HIV-1 reservoir cells in vivo.
Introduction
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RESULTS
1
HIV-1 persistence in both T and myeloid cells in NRG-hu HSC mice during cART
2 NRG-hu HSC mice (hu-mice) were infected with HIV JRCSF and monitored for viral load and HIV-1 3 pathogenesis in peripheral blood until 14 weeks post-infection (wpi). Several infected animals 4 were treated with cART in mouse diet from 4-to-12 wpi. We showed that plasma viral load 5 declined rapidly after initiation of cART, concomitant with a recovery of peripheral blood CD4 + T 6 cells ( Fig. 1A and Fig. S1A ). Viral load reached undetectable levels in treated mice around 3-4 7 weeks after cART ( Fig. 1A ). We kept cART on board four more weeks before withdraw at 12wpi. 8 As observed in HIV-1 patients, plasma viral load rebounded rapidly after discontinuation of 9 cART ( Fig. 1A) , correlated with a decrease of human CD4 + T cells in the blood (Fig. S1A ). At 12 10 wpi before cART cessation, three mice in each group were terminated for determining HIV-1 11 replication and pathogenesis in lymphoid tissues. The results demonstrated that HIV-1 gag p24 12 was significantly detected in both CD4 T cells (huCD45 + CD3 + CD8 -) and monocytic cells 13 (huCD45 + CD3 -CD11c + CD14 + ) in spleens and BM in cART-naïve mice. Accordingly, cART abolished 14 p24 expression in both cell populations ( Fig. 1B-E) . Meanwhile, the CD4 + T cell level in cART-15 treated mice was significantly recovered, whereas a marked deletion of CD4 + T cells was 16 observed in cART naïve-treated mice ( Fig. S1A-C) . The increase of CD4 + T cell percentage 17 correlated with a dramatic recovery of CD4 + T cell number in lymphoid tissues ( Fig. S1D ). As we 18 reported previously, cART-resistant replication-competent HIV-1 reservoirs persist ( Fig. S2A ), 19 though cell-associated HIV-1 RNA and DNA was remarkably decreased by cART in lymphoid 20 tissues ( Fig. S2B and C) (28, 29), and viremia rebounded upon cART cessation (Fig. 1A) . However, 21 7 the detection of p24 in monocytic cells could be due to their phagocytosis of HIV-1 infected 1 CD4 + T cells(30). In order to investigate whether monocytic cells could be infected by HIV-1, and 2 more importantly, play a role as HIV-1 reservoirs during cART, we purified human CD3 -3 CD11c + CD14 + monocytic cells and CD3 + CD8 -(CD4) T cells from bone marrow cells in animals 4 with undetectable HIV-1 p24 positive cells by flow cytometry. We first measured cell-associated 5 HIV-1 DNA by real-time PCR. In addition, purified monocytic cells was stimulated with TNF-α for 6 24 hours and then co-cultured with MOLT-4 cells to detect replication-competent virus. Total 7 bone marrow cells from the same animals were used as controls. The results revealed that 8 monocytic cells harbored more HIV-1 DNA per million cells on average than CD4 T cells ( Fig. 1F ). 9 Notably, replication-competent viruses could be recovered from monocytic cells ( Fig.1G) , 10 suggesting monocytic cells as well as CD4 T cells harbored replication-competent HIV-1 during 17 Bromodomain inhibitors have been shown to activate HIV-1 gene expression in different cell 18 systems in vitro with latent or chronic HIV-1 infection (24-27). However, little is known about 19 how bromodomain inhibitors affect HIV-1 reservoirs in vivo during cART. In order to investigate 20 the effect of BETi on viral reservoirs in vivo, we first characterized the pharmacokinetic (PK) 21 properties of I-BET151 in NSG mice. We showed that, at dose of 18mg/kg, the concentration of 22 I-BET151 was maintained for at least 8 hours in blood and dropped below EC 50 around 24 hours 1 after the initial administration through gavage ( Fig. S3 ). Thus, humanized mice were treated 2 with I-BET151 once every 20 hours in the following experiments. To assess the capacity of I-3 BET151 in activating HIV-1 reservoir cells, HIV-1 infected hu-mice were treated with I-BET151 at 4 21wpi by daily gavage after viremia was completely suppressed for 4 weeks by cART. HIV-1 5 viremia rebound was detected on day 9 (22.3wpi) after I-BET151 treatment ( Fig. 2A ). To catch 6 the putative HIV-1 reservoir cells responding to I-BET151 treatment, animals were terminated 7 immediately after viremia rebound was detected. Leukocytes from spleens and bone marrow as In order to define the HIV-1 reservoir cells that were activated by BETi, we investigated what 18 cell types were responding to I-BET151 treatment in vivo. Surprisingly, we did not observe any 19 activation of p24 production in CD4 T cells ( Fig. 3A and B ), but a significant percentage of 20 monocytic cells became p24-positive after I-BET151 treatment ( Fig. 3C and D) . And we did not 21 observe significant p24 expression in other cell types (Data not shown). To confirm this finding, 22 we performed immune-fluorescence staining on spleen tissue sections. Either human CD3/p24 1 or CD14/p24 were co-stained by specific antibodies. Consistently, we found p24 staining was 2 co-localized with CD14 positive cells in I-BET151 group but not with CD3 positive cells. In 3 comparison, no p24 positive cells were detected in cART-only mice, indicating an effective 4 suppression of HIV-1 replication by cART ( Fig. 3E ). Accordingly, when we normalized cell-5 associated HIV-1 RNA to the level of human CD14 gene, a more significant increase of HIV-1 6 RNA level was observed as compare to normalization to human CD4 gene ( Fig. 2B and Fig. S4 ). 7 We calculated CD3 -CD11c + CD14 + monocytic cell numbers in the spleen, and found I-BET151 did 8 not alter the number of cells in treated group (Fig. 3F ). However, the p24 positive monocytic 9 cell number was significantly increased by I-BET151 treatment (Fig. 3G ). Similar findings were 10 also observed in the bone marrow ( Fig. S5 ). In a separate experiment with sustained cART, the 11 elevated viral load induced by I-BET15 treatment could be inhibited again when I-BET151 was 12 stopped (Data not shown), indicating that the observed rebound of viral RNA production was 13 not due to the emergence of drug-resistant mutant viruses. In addition, neither percentage nor 14 total number of CD4 + T cells or huCD45 + cells in I-BET151-treated animals was affected in 15 comparison to non-treated mice ( Fig. S6 ). Thus, I-BET151 treatment did not mediate significant 16 cytotoxicity in vivo in this study. Together, our results suggest that I-BET151 treatment 21 It has been reported that BETi activates HIV-1 gene transcription in latent models of both T cells 1 and monocytic cells in vitro (26, 27) . To confirm our finding, we transduced either resting CD4 + 2 T cells or monocyte derived macrophages (MDMs) with VSV-G HIV Duo-Fluo, which can 3 distinguish productive infection from latent infection. This reporter virus encodes two separate 4 fluorescent markers: an LTR-driven eGFP marker (productive infection) and an LTR-independent 5 mCherry marker driven by an EF1α promoter (31, 32) . After transduction, cells were cultured 6 for 24 hours before I-BET151 treatment. mCherry and GFP expression was determined at 72 7 hours for CD4 + T cells and 36 hours for MDMs after culture with I-BET151 ( manner. However, I-BET151 enhanced viral gene transcription in U1 cells at about 5-to-10 fold 20 more efficiently than in ACH-2 cells using the same dose ( Fig. 5A and 4B ). An approximate 3-fold 21 difference in EC 50 was observed as calculated based on the viral transcription levels (Fig. 5C ). 22 We speculated that the quiescent status of HIV-1 provirus may contribute to this 1 discrepancy observed in different cell types. Thus, we inoculated U937 cells and Jurkat cells 2 with the dual reporter virus and sorted the mCherry + GFPcells (latent infection). After culturing 3 for 4 days to expand the cells, we treated Jurkat-DuoFluo or U937-DuoFluo cells with I-BET151 4 (0.5μM) for 48 hours. The activation of HIV transcription was indicated by the percent of GFP Inhibition of either cyclin-dependent kinase (CDK) 2 or CDK9 has been reported to suppress 14 HIV-1 transcription or replication in vitro or in vivo(36-41). Previous reports show that 15 bromodomain inhibitors induced reactivation of HIV-1 latency is dependent on CDK9 (24, 25). 16 HIV-1 replication, in CDK2-knockdown macrophages-like cells derived from pluripotent stem 17 cells, was significantly reduced (42) . To further study the mechanism of I-BET151-mediated HIV-18 1 transcription in monocytic cells and CD4 + T cells, we first established cell lines expressing 19 luciferase under the control of HIV-1 LTR using either U937 (U937-luc) or Jurkat (Jurkat-luc) cells. 20 We treated cells with I-BET151 in the presence of either CDK2 inhibitor (K03861)(43) or CDK9 21 inhibitor (LDC000067), and cultured for 48 hours before luciferase activity detection. In U937-22 luc cells, either CDK2 or CDK9 inhibitor alone could down-regulate HIV-1 transcription relative 1 to mock cells. When I-BET151 was introduced, the enhancement of HIV-1 transcription was 2 abolished by either CDK2 (1µM) or CDK9 (25µM) inhibitors ( Fig. 6A ). Interestingly, CDK2 3 inhibitor failed to inhibit I-BET151-induced HIV-1 transcription, even increased HIV-1 4 transcription in Jurkat-luc cells. While CDK9 inhibitor was able to down-regulate HIV-1 5 transcription and inhibit the activity of I-BET151 to enhance HIV transcription in Jurkat-luc cells 6 ( Fig. 6B ). These results suggested that the different efficacy of I-BET151 in activating HIV-1 7 transcription in monocytic cells and CD4 + T cells is attributed to cell-intrinsic difference in the 8 regulation of HIV-1 transcription by CDK2. Despite the importance of HIV-1 reservoirs in resting CD4 + T cells, it is impossible to achieve a 2 cure without considering reservoirs cells like macrophages in brain tissues (44, 45) . The 3 existence of HIV-1 macrophages reservoirs in vivo is strongly supported by Honeycutt et al (17), 4 who demonstrated that HIV-1 replication can be sustained in macrophages in a humanized 5 mice model without T cells. Consistently, our study demonstrates that monocytes or 6 macrophages are important HIV-1 reservoir cells during suppressive cART. Importantly, 7 bromodomain inhibitors could be a novel measure adopted to activate viral replication in this 8 particular reservoir in vivo. 9 It is known that HIV-1 reservoir cells can be exit in two different statuses in vivo. One is 10 harboring latent replication-competent proviruses expressing little to no viral products. The 11 long-lived resting memory CD4 + T cells is the putative latent reservoir cells mostly studied to 12 date (46-48). The other kind of reservoir cells is the residual active reservoir cells which 13 consistently produce low level of viruses, because of either sanctuary sites that have low 14 accessibility to cART, or the cell types that less responsive to certain anti-retroviral drugs such 15 as monocytes or macrophages(49-51). The very recent report proved the existence of lymphoid 16 tissue sanctuary sites for harboring low level of viral replication in patients with undetectable 17 viremia (52). And the brain resident macrophages have been considered to play a pivotal role in 18 maintaining HIV-1 persistent infection since cART in brain is not as effective as in other tissues 19 (44, 45) . In our study, we cannot distinguish if the increased level of HIV-1 replication in 20 monocytic cells is due to activation of HIV provirus or enhancement of residual low level of viral 21 replication. However, our findings are valuable for HIV reservoir study and development of 1 strategies targeting to different persistently infected cells during cART. 2 In this study, no reduction of cell-associated HIV-1 DNA in human cells was observed solely by 3 I-BET151 treatment on day 9 after the administration. We speculate that the poor elimination Total RNA was extracted from cells or tissues using RNeasy plus mini kit (Qiagen). HIV-1 RNA 19 was detected as previously described (28, 29, 60) . The HIV-1 gag RNA expression were 20 normalized to human CD4 or CD14 mRNA level and relative HIV-1 gene expression levels were 21 calculated according to 2 -ΔΔCT (29, 65). Bromodomain inhibitor I-BET151 was obtained from GlaxoSmithKline (Research Triangle Park, 20 NC). Drug powder was dissolved in 0.5%HPMC:0.1%Tween80 to a final concentration of 1.5 21 mg/ml and pH 5. Administration of the drug was through daily oral gavage at dose of 18mg/kg. 1 The solvent without drug was used as placebo. Highly potent and specific CDK2 inhibitor 2 (K03861) and CDK9 inhibitor (LDC000067) (Selleckchem) were dissolved in DMSO and diluted to 3 the indicated concentration in medium before use. 
Bromodomain inhibitor activates HIV-1 replication under suppressive cART in vivo
I-BET151 activates HIV-1 reactivation more efficiently in monocytic cells than in T cells
Highlights
• BET-151 preferentially activate HIV-1 infection in CD3-CD11c+CD14+ monocytic cells as compare to CD4 T cells during suppressive cART in vivo .
• CD3-CD11c+CD14+ monocytic cells harbor replication-competent provirus during cART.
• BET-151 reactivate HIV-1 transcription and enhance viral replication in CD3-CD11c+CD14+ monocytic cells more than in resting CD4 T cells.
• BET151-induced activation of HIV-1 replication in monocytic cells is dependent on both CDK2 and CDK9, whereas only CDK9 is involved in the activation of HIV-1 replication mediated by BET151 in T cells. 
